Peanut oral immunotherapy: balancing benefits and risks for individuals

Affiliations

¹ Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK; NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK; The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UK. Electronic address: g.c.roberts@soton.ac.uk.
² Primary Care and Population Sciences, University of Southampton, Southampton, UK.

Comment

Graham Roberts et al. Lancet. 2019.

. 2019 Jun 1;393(10187):2180-2181.

doi: 10.1016/S0140-6736(19)30767-6. Epub 2019 Apr 26.

¹ Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK; NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UK; The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Isle of Wight, UK. Electronic address: g.c.roberts@soton.ac.uk.
² Primary Care and Population Sciences, University of Southampton, Southampton, UK.

No abstract available

Comment on

Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety.
Chu DK, Wood RA, French S, Fiocchi A, Jordana M, Waserman S, Brożek JL, Schünemann HJ. Chu DK, et al. Lancet. 2019 Jun 1;393(10187):2222-2232. doi: 10.1016/S0140-6736(19)30420-9. Epub 2019 Apr 25. Lancet. 2019. PMID: 31030987